IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.120
-0.030 (-2.61%)
At close: Dec 20, 2024, 4:00 PM
1.110
-0.010 (-0.89%)
After-hours: Dec 20, 2024, 5:55 PM EST
IceCure Medical Employees
As of December 31, 2023, IceCure Medical had 77 total employees, including 71 full-time and 6 part-time employees. The number of employees increased by 5 or 6.94% compared to the previous year.
Employees
77
Change (1Y)
5
Growth (1Y)
6.94%
Revenue / Employee
$47,675
Profits / Employee
-$179,662
Market Cap
61.35M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77 | 5 | 6.94% |
Dec 31, 2022 | 72 | 8 | 12.50% |
Dec 31, 2021 | 64 | 17 | 36.17% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Apyx Medical | 252 |
Vor Biopharma | 168 |
VolitionRx | 110 |
Immuneering | 68 |
Forian | 37 |
PDS Biotechnology | 25 |
Annovis Bio | 16 |
ICCM News
- 5 days ago - Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - PRNewsWire
- 25 days ago - IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - PRNewsWire
- 26 days ago - IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office - PRNewsWire
- 4 weeks ago - IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PRNewsWire
- 4 weeks ago - IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - PRNewsWire
- 6 weeks ago - FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - PRNewsWire
- 7 weeks ago - Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - PRNewsWire